OSURHealthcare · Medical Instruments & SuppliesThe 1 Wall Street analysts covering OraSure Technologies, Inc. hold a median 12-month price target of $4 — +5.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 24 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores OraSure Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (89): Analysts have, on balance, been raising their forecasts.
Quality (33): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OSUR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +5.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2025 | Stephens & Co. | Maintains | Equal-Weight | $3.50 → $3.00 |
| 19 May 2025 | Evercore ISI Group | Maintains | In-Line | — |
| 8 May 2025 | Evercore ISI Group | Maintains | In-Line | — |
| 7 Aug 2024 | Evercore ISI Group | Maintains | In-Line | — |
| 2 July 2024 | Evercore ISI Group | Maintains | In-Line | — |
| 13 May 2024 | JP Morgan | Maintains | Neutral | — |
| 4 Apr 2024 | Evercore ISI Group | Maintains | In-Line | — |
| 29 Feb 2024 | JP Morgan | Maintains | Neutral | — |
| 11 Dec 2023 | Citigroup | Maintains | Buy | — |
| 8 Nov 2023 | JP Morgan | Maintains | Neutral | — |
| 17 July 2023 | Stephens & Co. | Maintains | Equal-Weight | — |
| 11 May 2022 | Citigroup | Maintains | Buy | — |
| 24 Feb 2022 | Citigroup | Maintains | Buy | — |
| 22 Sept 2021 | Raymond James | Downgrade | Market Perform | — |
| 4 Aug 2021 | Raymond James | Maintains | Outperform | — |
| 28 June 2021 | Raymond James | Maintains | Outperform | — |
| 6 May 2021 | Raymond James | Maintains | Outperform | — |
| 21 Aug 2020 | Evercore ISI Group | Initiates | Outperform | — |
| 10 Aug 2020 | Citigroup | Initiates | Buy | — |
| 10 Aug 2020 | JP Morgan | Initiates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OSUR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 25 Aug 2026, OraSure Technologies, Inc. returned +20.4% against +20.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 39% of US stocks
Cheaper than 49% of US stocks
Cheaper than 79% of US stocks
Cheaper than 70% of US stocks
Higher than 24% of US stocks
Higher than 55% of US stocks
Higher than 16% of US stocks
Higher than 11% of US stocks
Higher than 34% of US stocks
Higher than 26% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
OraSure Technologies, Inc. has a market value of $263.5M and an enterprise value of $115.0M.
Revenue in the twelve months to 30 June 2026: $112.4M. The latest quarter shrank 1.9% year on year.
Net income over the same four quarters: −$49.1M, a −43.7% net margin.
Diluted earnings per share, trailing twelve months: $−0.69.
Free cash flow in the twelve months to 30 June 2026: −$48.1M.
OraSure Technologies, Inc. spent $18.9M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 19.9×; forward P/E: −5.8× — the forward figure prices analyst consensus estimates, not reported earnings.
OraSure Technologies, Inc. employs 500 people — $225K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own OraSure Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of OraSure Technologies' (OSUR) Q2 2026 earnings call, based on the company's recent earnings event. The excerpt offers the headline and source only, with no additional details on results.
Why it matters — An OSUR watcher would care because the transcript gives access to management's commentary on the company's second-quarter 2026 performance.
OraSure Technologies reported second-quarter revenue of $30.6 million, surpassing its guidance range and growing 9.7% sequentially. The company attributed the results to stronger public-health diagnostics demand and growth in its sample-management products.
Why it matters — OSUR watchers would care because the company beat its own revenue guidance on sequential growth in two key product areas.
OraSure Technologies announced its financial results for the three months ended June 30, 2026 (second quarter 2026), via a press release issued on August 5, 2026, out of its Bethlehem, Pennsylvania headquarters.
Why it matters — OSUR watchers would look to this announcement for the company's official quarterly financial performance disclosure for the period.
The 1 Wall Street analysts covering OraSure Technologies, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering OraSure Technologies, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OraSure Technologies, Inc. 88 out of 100 across roughly 4,600 US stocks as at 24 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Aug 2026, OraSure Technologies, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (89 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +5.8% from the last close, and Ticker Nerd's factor model ranks OraSure Technologies, Inc. 88 out of 100 as at 24 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering OraSure Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSUR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.
OraSure Technologies, Inc. returned +20.4% over the 12 months to 25 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Orasure Technologies Inc. is a biotechnology company primarily focused on developing point-of-care diagnostic testing and specimen collection devices.
The most recent item we track (Seeking Alpha, 6 Aug 2026): "OraSure Technologies, Inc. (OSUR) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of OraSure Technologies' (OSUR) Q2 2026 earnings call, based on the company's recent earnings event. The excerpt offers the headline and source only, with no additional details on results.
Orasure Technologies Inc. is a biotechnology company primarily focused on developing point-of-care diagnostic testing and specimen collection devices. Known for its innovation in oral fluid diagnostics, Orasure provides critical solutions in the healthcare sector. Their product portfolio includes diagnostic tests for infectious diseases, such as HIV and Hepatitis C, leveraging easy-to-use, rapid results that are essential for timely medical interventions. Additionally, Orasure offers services and tools for the life sciences, including molecular sample collection and stabilization products utilized in genetic and microbiome research. The company's products serve a diverse range of sectors, including hospitals, clinics, and public health organizations, contributing significantly to both disease prevention and management. Headquartered in Bethlehem, Pennsylvania, Orasure Technologies plays a pivotal role in advancing public health infrastructure by offering reliable, user-friendly diagnostic tools that empower healthcare providers and patients alike. In the broader market context, Orasure addresses the growing demand for at-home and rapid testing solutions, which have become increasingly crucial components of modern healthcare systems worldwide.
CEO Ms. Carrie Eglinton Manner · 500 employees · United States · https://www.orasure.com
